摘要:
L'invention concerne des plasmides d'expression bactérienne de polypeptides comprenant une partie substantielle de la séquence d'acides aminés, et présentant l'activité biologique, d'un des domaines de fibronectine humaine se produisant naturellement, tel que le domaine de liaison de cellules ou le domaine de liaison de fibrine, comprenant de l'ADN codant le polypeptide et de l'ADN codant des éléments régulateurs adaptés positionnés par rapport à lADN codant le polypeptide, de manière à procéder à l'expression du polypeptide dans une cellule hôte adéquate. Dans le mode de réalisation actuellement préféré de l'invention, le polypeptide est un polypeptide 75 kD, 40 kD ou 33 kD du domaine de liaison de cellules, ou un polypeptide 31 kD ou un 20 kD du domaine de liaison de fibrine. L'invention concerne également des procédés de production des polypeptides ainsi que des compositions pharmaceutiques les comprenant et des supports pharmaceutiquement acceptables. On peut utiliser les polypeptides de l'invention afin d'inhiber l'agrégation de plaquettes, d'inhiber la libération de thromboxane par les plaquettes, ou afin de traiter un sujet atteint de troubles cérébrovasculaires, de troubles cardiovasculaires, souffrant d'une blessure, d'une infection bactérienne, d'un cancer ou afin de détecter un thrombi de fibrine. L'invention concerne en outre les polypeptides conjugués à des agents thrombolytiques, des facteurs de croissance, de l'albumine de sérum, des facteurs sanguins ou du polyéthylène-glycol.
摘要:
@ An improved vector upon introduction into a suitable bacterial host containing the thermolabile repressor Ct renders the host cell capable, upon increasing the temperature of the host cell to a temperature at which the repressor is destroyed, of effecting expression of a desired gene inserted into the vector and production of polypeptide encoded by the gene. The vector is a double-stranded DNA molecule which includes In 5' to 3' order the following: a DNA sequence which contains the promoter and operator PLOL from lambda bacteriophage; the N utilization site for binding ant i terminator N protein produced by the host cell; a DNA sequence which contains a ribosomal binding site for rendering the mRNA of the desired gene capable of binding to ribosomes within the host cell; and ATG initiation codon or a DNA sequence which is converted Into an ATG initiation codon upon insertion of the desired gene into the vector; a restriction enzyme site for inserting the desired gene into the vector in phase with the ATG initiation oodon; and additionally a DNA sequence which contains an origin of replication from a bacterial plasmid capable of autonomous replication in the host cell and a DNA sequence which contains a gene associated with a selectable or identifiable trait which is manifested when the vector is present in the host cell.
摘要:
A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism containing cDNA encoding the polypeptide has been deposited in the ATCC under Accession No. 69134. Recombinant microorganisms able to produce the polypeptide have been deposited in the ATCC under Accession Nos. 69135, 69137 and 69269.
摘要:
The subject invention provides novel peptides and the use of these peptides in the treatment of various diseases and conditions. The novel peptides specifically bind to undetermined and determined targets in various organs and in lymphocytes. The subject invention also provides a method for the identification of a peptide by applying peptide library methodology ex vivo to perfused organs.
摘要:
This invention provides an imaging agent which comprises a polypeptide labeled with an imageable marker, such polypeptide having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin. The invention further provides a method wherein the imaging agent is used for imaging a fibrin-containing substance, i.e., a thrombus or atherosclerotic plaque. Further provided are plasmids for expression of polypeptides having an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and being capable of binding to fibrin, hosts containing these plasmids, methods of producing the polypeptides, methods of treatment using the polypeptides, and methods of recovering, refolding and reoxidizing the polypeptides. The invention also provides for purified polypeptides substantially free of other substances of human origin which have an amino acid sequence substantially present in the fibrin binding domain of naturally-occuring human fibronectin and which are capable of binding to fibrin.
摘要:
A method of contraception is disclosed which comprises a two-stage protocol. In the first stage, an estrogenic compound in a first composition is administered daily as the sole contraceptively active substance to a human female from about Day 2 to about Day 7 of her menstrual cycle, where Day 1 is the first day of menses. The second stage of the protocol occurs immediately thereafter during which at least one follow-up composition containing a progestin is administered daily to the same human female. The follow-up composition can contain a progestin as the sole contraceptively active ingredient, or can contain a combination of an estrogenic compound with a progestin in different weight ratios. A drug delivery system containing daily dosage units is also described.
摘要:
A method of sequentially removing one or more N-terminal amino acid residues from an analog of a eucaryotic polypeptide synthesized in a foreign host, comprises contacting the eucaryotic polypeptide analog with aminopeptidase under suitable conditions permitting sequential removal of N-terminal amino acid residues, where the polypeptide analog contains amino acid residue or sequence of residues which blocks the action of an aminopeptidase located at a position other than the N-terminal end of the polypeptide analog. A specific embodiment of the invention concerns removing both an N-terminal methionine residue and its adjacent Leucine residue from a growth hormone analog produced in bacteria by contacting the growth hormone analog with Aeromonas aminopeptidase under suitable conditions permitting removal of the N-terminal methionine and Leucine residues. The invention also concerns eucaryotic polypeptide analogs produced in accordance with the methods of the invention.
摘要:
The invention relates to a method of producing a human growth hormone having the amino acid sequence of naturally occurring human growth hormone which comprises a) producing in a microbial host a first polypeptide which is characterized by the presence of one or more additional amino acids at the N-terminus of the amino acid sequence of naturally occurring human growth hormone; b) contacting the first polypeptide so produced with an enzyme, preferably an aminopeptidase, so as to produce a second polypeptide having the amino acid sequence of naturally occurring human growth hormone; and c) recovering the second polypeptide so produced. A preferred microbial host is a bacterium, especially E. coli .